nicotine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1920 54-11-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nicotine
  • L-Nicotine
  • (S)-Nicotine
  • (-)-Nicotine
  • nicotine bitartrate anhydrous
  • nicotine polacrilex
Devices or delivery systems used to aid in ending a TOBACCO habit.
  • Molecular weight: 162.24
  • Formula: C10H14N2
  • CLOGP: 0.88
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 16.13
  • ALOGS: -0.24
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg Chewing gum
60 mg Inhal
30 mg N
30 mg SL
14 mg TD

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 16.70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.52 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.95 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.126 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.745 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 17.179 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 6.998 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 64.540 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 59.110 % High 1
herg hERG pIC50 4.278 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.633 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 4.667 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 62.510 % High 1
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,EIF2AK3,ERBB2,FLT3,GRK2,IRAK4,ITK,JAK3,MAPK7,NTRK2,PDK2,PDK4,PRKDC,SIK2,SIK3,TEK,TGFBR1 25
kinase-selectivity-class AXL,BRAF,CAMK2D,CDK4,CDK9,EIF2AK3,EPHB4,ERBB2,IRAK1,MARK4,PRKCD,SIK2,SYK 13
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.611 High 1
mh-clint Mouse hepatocyte intrinsic clearance 13.868 High 1
mppb Mouse plasma protein binding (% unbound) 87.750 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.742 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 73.050 % High 1
rh-clint Rat hepatocyte intrinsic clearance 3.428 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 89.530 % High 1
rppb Rat plasma protein binding (% unbound) 65.940 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 500.035 uM High 1

Approvals:

DateAgencyCompanyOrphan
Nov. 7, 1991 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 1135.02 15.08 416 24243 37554 90566234
Nicotine dependence 654.04 15.08 128 24531 922 90602866
Chronic sinusitis 469.33 15.08 193 24466 23609 90580179
Vaginal flatulence 397.64 15.08 144 24515 12494 90591294
Paraesthesia oral 385.50 15.08 183 24476 31476 90572312
Proctitis 371.21 15.08 144 24515 15115 90588673
Female genital tract fistula 355.99 15.08 146 24513 17722 90586066
Vaginal discharge 353.93 15.08 149 24510 19315 90584473
Radiculopathy 344.32 15.08 144 24515 18361 90585427
Procedural pain 314.41 15.08 162 24497 33198 90570590
Drug withdrawal syndrome neonatal 298.49 15.08 78 24581 2241 90601547
Oral candidiasis 268.90 15.08 149 24510 35306 90568482
Drug dependence 266.53 15.08 139 24520 29188 90574600
Premature delivery 232.90 15.08 140 24519 38622 90565166
Foetal exposure during pregnancy 212.17 15.08 137 24522 42838 90560950
Colitis 206.53 15.08 163 24496 69779 90534009
Colitis ulcerative 205.47 15.08 153 24506 60113 90543675
Frequent bowel movements 204.14 15.08 149 24510 56786 90547002
Product adhesion issue 197.58 15.08 68 24591 5074 90598714
Haematochezia 187.63 15.08 155 24504 70758 90533030
Incorrect product administration duration 182.48 15.08 94 24565 19228 90584560
Rectal haemorrhage 170.79 15.08 157 24502 82587 90521201
Therapeutic product effect incomplete 169.50 15.08 235 24424 193661 90410127
Overdose 160.62 15.08 206 24453 157503 90446285
Constipation 103.93 15.08 233 24426 280162 90323626
Erythema 98.14 15.08 202 24457 229044 90374744
Premature baby 92.95 15.08 67 24592 25010 90578778
Application site erythema 91.73 15.08 39 24620 5169 90598619
Dyspepsia 91.23 15.08 180 24479 197980 90405808
Myocardial stunning 89.27 15.08 20 24639 293 90603495
Application site pruritus 85.56 15.08 35 24624 4212 90599576
Drug abuse 84.42 15.08 108 24551 82239 90521549
Arthropathy 82.98 15.08 4 24655 366238 90237550
Toxicity to various agents 82.86 15.08 217 24442 287629 90316159
Dependence 81.63 15.08 28 24631 2067 90601721
Rib deformity 80.45 15.08 18 24641 262 90603526
Truncus arteriosus persistent 79.15 15.08 19 24640 382 90603406
Jaundice neonatal 79.11 15.08 23 24636 987 90602801
Tobacco abuse 76.86 15.08 21 24638 717 90603071
Systemic lupus erythematosus 75.85 15.08 6 24653 361890 90241898
Low birth weight baby 75.07 15.08 41 24618 9426 90594362
Joint swelling 74.98 15.08 22 24637 503278 90100510
Maternal exposure during pregnancy 72.52 15.08 239 24420 359824 90243964
Rhesus incompatibility 71.13 15.08 14 24645 104 90603684
Congenital cardiovascular anomaly 70.15 15.08 18 24641 480 90603308
Alopecia 69.55 15.08 24 24635 495047 90108741
Drug ineffective 69.45 15.08 625 24034 1383673 89220115
Accidental overdose 68.94 15.08 59 24600 28214 90575574
Intentional product misuse 68.49 15.08 102 24557 89502 90514286
Necrosis ischaemic 66.33 15.08 20 24639 975 90602813
Rheumatoid arthritis 65.93 15.08 10 24649 362604 90241184
Abdominal pain 65.32 15.08 246 24413 395475 90208313
Sputum purulent 64.31 15.08 21 24638 1331 90602457
Poor feeding infant 63.67 15.08 17 24642 531 90603257
Weight decreased 62.55 15.08 236 24423 379674 90224114
Chronic obstructive pulmonary disease 62.18 15.08 88 24571 73741 90530047
Treatment failure 61.08 15.08 6 24653 303922 90299866
Glossodynia 60.54 15.08 8 24651 321771 90282017
Cardiac septal defect 57.63 15.08 17 24642 768 90603020
Therapeutic product effect decreased 57.05 15.08 5 24654 277566 90326222
Reversible cerebral vasoconstriction syndrome 56.81 15.08 26 24633 4104 90599684
Arthralgia 56.27 15.08 78 24581 778444 89825344
Malaise 56.02 15.08 310 24349 585676 90018112
Substance abuse 55.98 15.08 28 24631 5378 90598410
Hepatic enzyme increased 55.12 15.08 15 24644 360721 90243067
Secondary immunodeficiency 55.02 15.08 21 24638 2105 90601683
Pneumonia streptococcal 54.87 15.08 21 24638 2120 90601668
Wound 53.61 15.08 9 24650 302971 90300817
Application site reaction 52.40 15.08 16 24643 814 90602974
Impaired healing 51.63 15.08 3 24656 234196 90369592
Contraindicated product administered 51.43 15.08 12 24647 320127 90283661
Oligohydramnios 51.12 15.08 29 24630 7172 90596616
Psoriatic arthropathy 50.11 15.08 3 24656 228332 90375456
Abdominal discomfort 49.17 15.08 35 24624 477293 90126495
Beta haemolytic streptococcal infection 48.16 15.08 20 24639 2499 90601289
Application site rash 47.05 15.08 20 24639 2649 90601139
Abortion induced 46.90 15.08 33 24626 11855 90591933
Swelling 46.86 15.08 28 24631 419030 90184758
Fatigue 46.61 15.08 160 24499 1153863 89449925
Anaemia 46.02 15.08 204 24455 352598 90251190
Reversible airways obstruction 45.68 15.08 18 24641 1965 90601823
Mobility decreased 45.36 15.08 7 24652 250727 90353061
Heart disease congenital 45.24 15.08 17 24642 1632 90602156
Discomfort 44.63 15.08 10 24649 274325 90329463
Nausea 44.07 15.08 478 24181 1109838 89493950
Musculoskeletal stiffness 44.04 15.08 13 24646 296519 90307269
Caesarean section 43.73 15.08 38 24621 18539 90585249
Exposure via breast milk 42.98 15.08 18 24641 2297 90601491
Condition aggravated 42.64 15.08 60 24599 595485 90008303
Infection 42.18 15.08 23 24636 362071 90241717
Maternal exposure during breast feeding 41.35 15.08 24 24635 6196 90597592
Nasal obstruction 40.89 15.08 18 24641 2594 90601194
Gastrointestinal disorder 40.48 15.08 10 24649 256677 90347111
Nasopharyngitis 40.42 15.08 31 24628 407073 90196715
Blister 40.08 15.08 10 24649 254988 90348800
Full blood count abnormal 39.07 15.08 49 24610 36548 90567240
Tobacco interaction 38.52 15.08 8 24651 80 90603708
Loss of proprioception 37.70 15.08 11 24648 478 90603310
Drug intolerance 37.39 15.08 40 24619 447551 90156237
Ventricular septal defect 36.31 15.08 21 24638 5386 90598402
Stomatitis 35.73 15.08 15 24644 274683 90329105
Axonal neuropathy 35.13 15.08 13 24646 1196 90602592
Exposure during pregnancy 35.03 15.08 143 24516 238267 90365521
Fibromyalgia 34.60 15.08 7 24652 206262 90397526
Congenital tricuspid valve incompetence 34.37 15.08 8 24651 140 90603648
Throat clearing 34.26 15.08 18 24641 3829 90599959
Contusion 33.84 15.08 13 24646 251203 90352585
Peripheral swelling 33.30 15.08 38 24621 413068 90190720
Diarrhoea 32.80 15.08 138 24521 939052 89664736
Application site irritation 32.28 15.08 14 24645 1947 90601841
Tobacco poisoning 32.09 15.08 7 24652 90 90603698
Type 2 diabetes mellitus 31.88 15.08 8 24651 203236 90400552
Drug screen positive 31.82 15.08 17 24642 3740 90600048
Product use in unapproved indication 31.62 15.08 27 24632 336209 90267579
Abdominal pain upper 30.94 15.08 27 24632 332647 90271141
Congenital pulmonary hypertension 30.00 15.08 7 24652 124 90603664
Chest X-ray abnormal 29.58 15.08 18 24641 5064 90598724
Ill-defined disorder 29.54 15.08 7 24652 184884 90418904
Maternal drugs affecting foetus 29.35 15.08 18 24641 5137 90598651
Treatment noncompliance 28.76 15.08 51 24608 51676 90552112
Application site dermatitis 28.48 15.08 7 24652 156 90603632
Developmental hip dysplasia 28.35 15.08 12 24647 1573 90602215
Product quality issue 28.28 15.08 65 24594 79260 90524528
Liver injury 28.17 15.08 6 24653 170561 90433227
Drug use disorder 28.00 15.08 21 24638 8322 90595466
Agitation neonatal 27.93 15.08 9 24650 547 90603241
Rash 27.75 15.08 117 24542 795983 89807805
Alcohol withdrawal syndrome 27.09 15.08 10 24649 914 90602874
Dysmetropsia 27.03 15.08 6 24653 84 90603704
Premature separation of placenta 26.74 15.08 13 24646 2349 90601439
Musculoskeletal pain 26.36 15.08 7 24652 171244 90432544
Suicidal ideation 25.76 15.08 60 24599 73795 90529993
Abnormal dreams 24.45 15.08 22 24637 11235 90592553
General physical health deterioration 24.18 15.08 37 24622 355078 90248710
Xanthogranuloma 24.13 15.08 4 24655 9 90603779
Symphysiolysis 23.30 15.08 4 24655 12 90603776
Application site swelling 22.71 15.08 8 24651 639 90603149
Gait inability 22.51 15.08 6 24653 146450 90457338
Maternal alcohol use 22.41 15.08 4 24655 16 90603772
Irritability 22.24 15.08 37 24622 35625 90568163
Lung disorder 21.47 15.08 7 24652 149876 90453912
Electrocardiogram QRS complex prolonged 21.39 15.08 17 24642 7331 90596457
Inflammation 21.28 15.08 11 24648 178581 90425207
Premature labour 21.23 15.08 22 24637 13354 90590434
Bursitis 21.00 15.08 5 24654 131649 90472139
Rhinitis 20.96 15.08 22 24637 13550 90590238
Upper-airway cough syndrome 20.69 15.08 23 24636 15112 90588676
Decreased appetite 20.50 15.08 45 24614 376495 90227293
Lower respiratory tract infection 20.24 15.08 23 24636 250636 90353152
Electrocardiogram PR shortened 20.18 15.08 7 24652 534 90603254
Cardiac death 19.61 15.08 7 24652 581 90603207
Sinusitis 19.51 15.08 40 24619 343048 90260740
Osteoarthritis 19.28 15.08 15 24644 195715 90408073
Withdrawal syndrome 19.18 15.08 27 24632 22497 90581291
Application site vesicles 19.15 15.08 9 24650 1508 90602280
Completed suicide 18.96 15.08 84 24575 144974 90458814
Disinhibition 18.81 15.08 8 24651 1060 90602728
Thunderclap headache 18.66 15.08 6 24653 362 90603426
Pubic pain 18.29 15.08 5 24654 171 90603617
Infusion related reaction 18.08 15.08 183 24476 416597 90187191
Antipsychotic drug level decreased 17.98 15.08 6 24653 407 90603381
Hypercholesterolaemia 17.82 15.08 3 24656 100889 90502899
Oedema 17.72 15.08 17 24642 200278 90403510
Obstructive airways disorder 17.71 15.08 28 24631 25841 90577947
False positive investigation result 17.57 15.08 7 24652 786 90603002
Pre-eclampsia 17.23 15.08 18 24641 11030 90592758
Nightmare 16.97 15.08 25 24634 21700 90582088
Application site scar 16.92 15.08 5 24654 227 90603561
Drug abuser 16.88 15.08 10 24649 2680 90601108
Alcohol abuse 16.66 15.08 9 24650 2024 90601764
Wrong technique in product usage process 16.64 15.08 50 24609 71521 90532267
Selective eating disorder 16.58 15.08 9 24650 2044 90601744
Anxiety 16.42 15.08 142 24517 309630 90294158
Application site burn 16.18 15.08 7 24652 967 90602821
Application site pain 16.10 15.08 12 24647 4708 90599080
Megacolon 15.94 15.08 9 24650 2205 90601583
Respiratory failure 15.79 15.08 69 24590 118349 90485439
Prinzmetal angina 15.71 15.08 7 24652 1038 90602750
Injection site reaction 15.70 15.08 3 24656 92077 90511711
Drug withdrawal syndrome 15.56 15.08 28 24631 28695 90575093
Therapy non-responder 15.44 15.08 9 24650 136695 90467093
Pulmonary fibrosis 15.43 15.08 5 24654 107498 90496290
C-reactive protein increased 15.35 15.08 16 24643 181373 90422415
Intentional product use issue 15.33 15.08 22 24637 216870 90386918
Foetal distress syndrome 15.25 15.08 8 24651 1697 90602091
Sudden infant death syndrome 15.13 15.08 5 24654 329 90603459

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 387.31 13.93 82 16499 611 42604143
Drug withdrawal syndrome neonatal 323.74 13.93 104 16477 4357 42600397
Drug dependence 283.79 13.93 163 16418 28931 42575823
Incorrect product administration duration 232.05 13.93 87 16494 5793 42598961
Overdose 226.54 13.93 240 16341 105024 42499730
Foetal exposure during pregnancy 213.75 13.93 164 16417 47147 42557607
Toxicity to various agents 213.03 13.93 345 16236 228791 42375963
Intentional product misuse 127.40 13.93 138 16443 61762 42542992
Premature baby 124.07 13.93 89 16492 23064 42581690
Product adhesion issue 115.80 13.93 38 16543 1701 42603053
Accidental overdose 103.95 13.93 87 16494 28243 42576511
Maternal exposure during breast feeding 103.62 13.93 34 16547 1521 42603233
Foetal disorder 81.72 13.93 26 16555 1053 42603701
Dependence 81.36 13.93 28 16553 1452 42603302
Low birth weight baby 79.29 13.93 49 16532 9906 42594848
Exposure via breast milk 74.14 13.93 30 16551 2447 42602307
Tobacco poisoning 73.25 13.93 13 16568 31 42604723
Alcohol abuse 69.00 13.93 33 16548 4016 42600738
Neutropenia neonatal 68.98 13.93 22 16559 898 42603856
Drug abuse 67.70 13.93 135 16446 104636 42500118
Jaundice neonatal 63.87 13.93 26 16555 2153 42602601
Tobacco abuse 59.88 13.93 18 16563 602 42604152
Drug screen positive 56.52 13.93 29 16552 4102 42600652
Poor feeding infant 54.45 13.93 18 16563 824 42603930
Drug abuser 51.85 13.93 26 16555 3505 42601249
Breech presentation 48.78 13.93 12 16569 184 42604570
Foetal distress syndrome 44.78 13.93 17 16564 1169 42603585
Tremor neonatal 41.88 13.93 13 16568 485 42604269
Alcohol interaction 41.31 13.93 19 16562 2116 42602638
Agitation neonatal 38.33 13.93 16 16565 1412 42603342
Off label use 37.99 13.93 125 16456 638210 41966544
Schizophrenia 37.85 13.93 32 16549 10518 42594236
Finnegan score increased 37.56 13.93 7 16574 24 42604730
Drug withdrawal syndrome 37.37 13.93 44 16537 21505 42583249
Withdrawal syndrome 34.00 13.93 35 16546 14740 42590014
Substance abuse 33.99 13.93 28 16553 8877 42595877
Application site pruritus 33.56 13.93 15 16566 1563 42603191
Application site erythema 32.20 13.93 17 16564 2549 42602205
Infant irritability 31.58 13.93 7 16574 66 42604688
Treatment noncompliance 31.13 13.93 54 16527 37618 42567136
Body temperature abnormal 30.34 13.93 12 16569 922 42603832
Rhesus incompatibility 27.73 13.93 6 16575 50 42604704
Hyperbilirubinaemia neonatal 27.71 13.93 11 16570 853 42603901
Regurgitation 27.65 13.93 14 16567 1926 42602828
Pneumonia acinetobacter 27.54 13.93 8 16573 237 42604517
Application site reaction 27.33 13.93 9 16572 407 42604347
Substance dependence 26.85 13.93 10 16571 652 42604102
Clostridium test positive 26.84 13.93 20 16561 5485 42599269
Choking 26.58 13.93 21 16560 6277 42598477
Floppy infant 26.25 13.93 7 16574 150 42604604
Application site rash 26.06 13.93 11 16570 998 42603756
Diarrhoea 25.47 13.93 93 16488 460756 42143998
Product quality issue 25.35 13.93 33 16548 17849 42586905
Venolymphatic malformation 24.69 13.93 5 16576 29 42604725
Tobacco user 24.42 13.93 9 16572 570 42604184
Vitamin B12 deficiency 24.26 13.93 18 16563 4904 42599850
Laryngeal dysplasia 23.37 13.93 4 16577 7 42604747
Ophthalmoplegia 23.23 13.93 13 16568 2187 42602567
Withdrawal catatonia 23.17 13.93 7 16574 238 42604516
Oropharyngeal discomfort 22.32 13.93 16 16565 4133 42600621
Product availability issue 22.10 13.93 15 16566 3552 42601202
Adulterated product 21.97 13.93 9 16572 757 42603997
Methaemoglobinaemia 21.71 13.93 18 16563 5756 42598998
Postmortem blood drug level increased 21.61 13.93 8 16573 513 42604241
Accidental death 21.61 13.93 14 16567 3069 42601685
Renal impairment 21.49 13.93 8 16573 110220 42494534
Infective exacerbation of chronic obstructive airways disease 21.43 13.93 12 16569 2021 42602733
Neonatal hypoxia 21.05 13.93 8 16573 552 42604202
Application site scar 20.09 13.93 4 16577 21 42604733
Chronic obstructive pulmonary disease 20.03 13.93 62 16519 63052 42541702
Acne infantile 20.01 13.93 5 16576 82 42604672
Insomnia 19.97 13.93 95 16486 118158 42486596
Ischaemic stroke 19.86 13.93 33 16548 22200 42582554
Brain stem syndrome 19.57 13.93 8 16573 669 42604085
Myocarditis 19.51 13.93 30 16551 18908 42585846
Drug use disorder 19.43 13.93 22 16559 10311 42594443
Agitation 19.32 13.93 62 16519 64252 42540502
Tachycardia 19.14 13.93 84 16497 101003 42503751
Reversible cerebral vasoconstriction syndrome 18.89 13.93 8 16573 732 42604022
Renal hypoplasia 18.80 13.93 5 16576 106 42604648
Depressed mood 18.64 13.93 33 16548 23351 42581403
Antipsychotic drug level increased 18.50 13.93 15 16566 4651 42600103
Dental caries 17.93 13.93 15 16566 4857 42599897
Pneumothorax spontaneous 17.86 13.93 8 16573 838 42603916
Sinus tachycardia 17.57 13.93 30 16551 20623 42584131
Pulmonary valve stenosis congenital 17.38 13.93 5 16576 143 42604611
Unresponsive to stimuli 17.36 13.93 38 16543 31365 42573389
Meningitis neonatal 17.26 13.93 3 16578 6 42604748
Weight decrease neonatal 17.00 13.93 6 16575 335 42604419
Maternal exposure during pregnancy 16.91 13.93 17 16564 6961 42597793
Disease progression 16.43 13.93 19 16562 143637 42461117
Eructation 16.39 13.93 15 16566 5471 42599283
Anxiety 16.35 13.93 90 16491 118470 42486284
Priapism 16.25 13.93 16 16565 6391 42598363
Palpitations 16.20 13.93 50 16531 50747 42554007
Application site vesicles 16.18 13.93 7 16574 675 42604079
Euphoric mood 16.15 13.93 16 16565 6437 42598317
Potentiating drug interaction 16.12 13.93 16 16565 6452 42598302
Breathing-related sleep disorder 16.09 13.93 5 16576 187 42604567
Application site urticaria 15.51 13.93 4 16577 75 42604679
Drug tolerance increased 15.36 13.93 6 16575 446 42604308
Neonatal disorder 15.05 13.93 7 16574 800 42603954
Necrotising ulcerative gingivostomatitis 14.90 13.93 4 16577 88 42604666
Loss of consciousness 14.72 13.93 73 16508 92281 42512473
Drug ineffective 14.63 13.93 166 16415 630031 41974723
Maternal drugs affecting foetus 14.50 13.93 12 16569 3827 42600927
Left ventricular hypertrophy 14.48 13.93 18 16563 9301 42595453
Cerebral congestion 14.30 13.93 4 16577 103 42604651
Emphysema 13.99 13.93 20 16561 11815 42592939
Mental status changes 13.94 13.93 42 16539 42073 42562681

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 674.39 13.01 139 33230 1192 110554738
Drug dependence 481.85 13.01 255 33114 49765 110506165
Chronic sinusitis 433.67 13.01 191 33178 24893 110531037
Vaginal flatulence 384.94 13.01 143 33226 12001 110543929
Macular degeneration 374.65 13.01 165 33204 21494 110534436
Paraesthesia oral 350.89 13.01 181 33188 33490 110522440
Female genital tract fistula 348.99 13.01 145 33224 16374 110539556
Proctitis 338.89 13.01 143 33226 16784 110539146
Vaginal discharge 337.70 13.01 145 33224 17763 110538167
Overdose 330.19 13.01 379 32990 233415 110322515
Radiculopathy 323.79 13.01 144 33225 19192 110536738
Incorrect product administration duration 303.19 13.01 140 33229 20358 110535572
Toxicity to various agents 301.58 13.01 528 32841 480027 110075903
Procedural pain 283.39 13.01 160 33209 35405 110520525
Oral candidiasis 227.33 13.01 151 33218 44609 110511321
Accidental overdose 180.53 13.01 139 33230 51695 110504235
Frequent bowel movements 166.79 13.01 152 33217 71238 110484692
Colitis ulcerative 163.94 13.01 156 33213 77207 110478723
Colitis 149.46 13.01 169 33200 102154 110453776
Drug abuse 142.06 13.01 218 33151 177193 110378737
Rectal haemorrhage 132.69 13.01 172 33197 119661 110436269
Therapeutic product effect incomplete 126.00 13.01 235 33134 223570 110332360
Intentional product misuse 123.21 13.01 175 33194 132729 110423201
Haematochezia 118.92 13.01 160 33209 115364 110440566
Application site erythema 104.34 13.01 45 33324 5565 110550365
Dyspepsia 98.20 13.01 193 33176 190772 110365158
Application site pruritus 96.29 13.01 39 33330 4121 110551809
Tobacco poisoning 91.42 13.01 18 33351 119 110555811
Tobacco abuse 88.53 13.01 26 33343 1040 110554890
Substance abuse 88.38 13.01 52 33317 12411 110543519
Myocardial stunning 85.22 13.01 20 33349 326 110555604
Product adhesion issue 82.95 13.01 32 33337 2974 110552956
Alcohol abuse 80.22 13.01 36 33333 4893 110551037
Reversible cerebral vasoconstriction syndrome 75.03 13.01 34 33335 4727 110551203
Drug screen positive 74.15 13.01 37 33332 6373 110549557
Rib deformity 70.98 13.01 16 33353 216 110555714
Rheumatoid arthritis 68.24 13.01 6 33363 299607 110256323
Application site reaction 67.46 13.01 20 33349 827 110555103
Constipation 66.51 13.01 248 33121 357538 110198392
Erythema 66.29 13.01 216 33153 291231 110264699
Drug abuser 64.87 13.01 32 33337 5377 110550553
Dependence 64.59 13.01 26 33343 2703 110553227
Chronic obstructive pulmonary disease 64.35 13.01 117 33252 109041 110446889
Drug use disorder 64.06 13.01 49 33320 18025 110537905
Application site rash 60.27 13.01 24 33345 2426 110553504
Arthropathy 59.78 13.01 8 33361 287514 110268416
Joint swelling 58.97 13.01 30 33339 442815 110113115
Systemic lupus erythematosus 58.17 13.01 5 33364 254333 110301597
Necrosis ischaemic 58.16 13.01 20 33349 1339 110554591
Therapeutic product effect decreased 55.34 13.01 5 33364 244311 110311619
Sputum purulent 55.22 13.01 21 33348 1877 110554053
Alopecia 52.76 13.01 22 33347 364731 110191199
Premature delivery 52.37 13.01 55 33314 30577 110525353
Pneumonia streptococcal 48.99 13.01 23 33346 3466 110552464
Hepatic enzyme increased 48.63 13.01 18 33351 320874 110235056
Drug withdrawal syndrome 47.45 13.01 58 33311 37996 110517934
Impaired healing 47.45 13.01 3 33366 196714 110359216
Beta haemolytic streptococcal infection 46.13 13.01 21 33348 2950 110552980
Arthralgia 45.80 13.01 105 33264 779527 109776403
Nasopharyngitis 45.08 13.01 32 33337 394329 110161601
Withdrawal syndrome 42.70 13.01 50 33319 31330 110524600
Glossodynia 42.04 13.01 8 33361 221996 110333934
Diarrhoea 41.50 13.01 190 33179 1139315 109416615
Drug intolerance 41.43 13.01 37 33332 406475 110149455
Treatment failure 41.26 13.01 16 33353 277218 110278712
Product availability issue 40.96 13.01 27 33342 7863 110548067
Infection 39.32 13.01 31 33338 362169 110193761
Alcohol interaction 38.86 13.01 20 33349 3674 110552256
Tobacco interaction 38.62 13.01 9 33360 142 110555788
Application site irritation 37.54 13.01 16 33353 1921 110554009
Abdominal pain 37.48 13.01 274 33095 512715 110043215
Psoriatic arthropathy 37.45 13.01 7 33362 196754 110359176
Postmortem blood drug level increased 37.34 13.01 14 33355 1203 110554727
Secondary immunodeficiency 37.12 13.01 21 33348 4655 110551275
Swelling 36.92 13.01 31 33338 351010 110204920
Application site scar 36.52 13.01 9 33360 182 110555748
Weight decreased 36.51 13.01 254 33115 467803 110088127
Gastrointestinal disorder 35.94 13.01 14 33355 241938 110313992
Fatigue 35.75 13.01 218 33151 1215740 109340190
Abdominal discomfort 35.38 13.01 40 33329 393818 110162112
Mobility decreased 34.83 13.01 14 33355 237408 110318522
Sinus tachycardia 34.61 13.01 54 33315 44439 110511491
Application site pain 33.97 13.01 21 33348 5478 110550452
Reversible airways obstruction 33.64 13.01 16 33353 2483 110553447
Malaise 33.28 13.01 329 33040 671490 109884440
Accidental death 33.17 13.01 20 33349 4989 110550941
Musculoskeletal stiffness 32.90 13.01 22 33347 279800 110276130
Fibromyalgia 32.69 13.01 6 33363 170903 110385027
Wound 32.52 13.01 15 33354 234422 110321508
Contusion 32.27 13.01 15 33354 233346 110322584
Nausea 32.17 13.01 537 32832 1235153 109320777
Peripheral swelling 32.15 13.01 45 33324 403989 110151941
Treatment noncompliance 30.72 13.01 68 33301 72922 110483008
Throat clearing 30.51 13.01 18 33351 4315 110551615
Suicidal ideation 30.36 13.01 79 33290 93858 110462072
Loss of proprioception 29.82 13.01 11 33358 903 110555027
Stomatitis 29.48 13.01 23 33346 270219 110285711
Euphoric mood 29.26 13.01 23 33346 8804 110547126
Nasal obstruction 29.20 13.01 16 33353 3334 110552596
Bipolar disorder 28.85 13.01 23 33346 8984 110546946
Unresponsive to stimuli 28.64 13.01 61 33308 63729 110492201
Substance dependence 28.44 13.01 10 33359 715 110555215
Loss of consciousness 28.41 13.01 126 33243 196180 110359750
Drug interaction 28.27 13.01 252 33117 499931 110055999
Osteoarthritis 28.07 13.01 10 33359 182613 110373317
Mental status changes 27.73 13.01 67 33302 76055 110479875
Contraindicated product administered 27.25 13.01 21 33348 248246 110307684
Application site dermatitis 27.03 13.01 7 33362 174 110555756
Maternal drugs affecting foetus 26.92 13.01 12 33357 1605 110554325
General physical health deterioration 26.81 13.01 55 33314 425240 110130690
Alcohol withdrawal syndrome 26.74 13.01 13 33356 2117 110553813
Joint range of motion decreased 26.26 13.01 3 33366 121829 110434101
Pneumonia acinetobacter 25.81 13.01 8 33361 385 110555545
Axonal neuropathy 25.69 13.01 13 33356 2305 110553625
Ophthalmoplegia 25.66 13.01 15 33354 3535 110552395
Full blood count abnormal 25.62 13.01 54 33315 55998 110499932
Product use in unapproved indication 25.62 13.01 61 33308 447316 110108614
Ischaemic stroke 25.29 13.01 45 33324 41218 110514712
Condition aggravated 25.23 13.01 125 33244 734711 109821219
Type 2 diabetes mellitus 25.11 13.01 11 33358 177221 110378709
Application site urticaria 24.85 13.01 7 33362 241 110555689
Renal impairment 24.71 13.01 13 33356 188432 110367498
Schizoaffective disorder 24.67 13.01 14 33355 3122 110552808
Dysmetropsia 24.36 13.01 6 33363 121 110555809
Application site vesicles 24.11 13.01 11 33358 1553 110554377
Pulmonary oedema 24.11 13.01 76 33293 100583 110455347
Musculoskeletal pain 23.45 13.01 13 33356 183010 110372920
Regurgitation 23.30 13.01 14 33355 3471 110552459
Liver disorder 23.25 13.01 7 33362 142236 110413694
Abdominal pain upper 22.98 13.01 44 33325 349067 110206863
Myocarditis 22.71 13.01 36 33333 30019 110525911
Decreased appetite 22.66 13.01 71 33298 475775 110080155
Antipsychotic drug level increased 22.65 13.01 18 33351 6997 110548933
Discomfort 22.51 13.01 19 33350 214688 110341242
Intentional overdose 22.24 13.01 89 33280 132412 110423518
Schizophrenia 22.08 13.01 30 33339 21796 110534134
Maternal alcohol use 21.99 13.01 4 33365 16 110555914
Infective exacerbation of chronic obstructive airways disease 21.81 13.01 13 33356 3177 110552753
Disease progression 21.66 13.01 25 33344 244009 110311921
Inflammation 21.64 13.01 16 33353 193222 110362708
Arthritis 21.33 13.01 12 33357 167574 110388356
Withdrawal catatonia 21.26 13.01 7 33362 410 110555520
Priapism 21.01 13.01 16 33353 5845 110550085
Tachycardia 20.68 13.01 128 33241 226517 110329413
Adulterated product 20.61 13.01 9 33360 1146 110554784
Cardiac arrest 20.45 13.01 115 33254 196638 110359292
Liver injury 20.28 13.01 10 33359 150403 110405527
Pubic pain 20.26 13.01 6 33363 247 110555683
Bursitis 20.16 13.01 7 33362 129911 110426019
Gait inability 20.06 13.01 8 33361 136368 110419562
Completed suicide 19.73 13.01 133 33236 242248 110313682
Hydrocele 19.72 13.01 9 33360 1272 110554658
Body temperature abnormal 19.53 13.01 12 33357 3097 110552833
Drug-induced liver injury 19.45 13.01 6 33363 120061 110435869
Application site swelling 19.45 13.01 8 33361 879 110555051
Anaemia 19.37 13.01 251 33118 546835 110009095
Arteriosclerosis 19.18 13.01 30 33339 24737 110531193
Product quality issue 19.10 13.01 59 33310 77240 110478690
Therapy non-responder 18.98 13.01 12 33357 157295 110398635
Arteriosclerosis coronary artery 18.86 13.01 30 33339 25088 110530842
Tobacco withdrawal symptoms 18.78 13.01 3 33366 4 110555926
Anxiety 18.52 13.01 172 33197 344906 110211024
Infusion related reaction 18.50 13.01 186 33183 380976 110174954
Methaemoglobinaemia 18.48 13.01 18 33351 9150 110546780
Lower respiratory tract infection 18.42 13.01 28 33341 243078 110312852
Emphysema 18.26 13.01 26 33343 19730 110536200
Foetal distress syndrome 18.25 13.01 7 33362 640 110555290
Application site discolouration 18.16 13.01 8 33361 1041 110554889
Derealisation 17.97 13.01 10 33359 2148 110553782
Clostridium test positive 17.63 13.01 19 33350 10874 110545056
Ill-defined disorder 17.55 13.01 13 33356 156840 110399090
Wrong technique in product usage process 17.41 13.01 62 33307 87286 110468644
Blister 17.41 13.01 26 33343 227350 110328580
Vitamin B12 deficiency 17.09 13.01 18 33351 10037 110545893
Mean cell volume decreased 17.07 13.01 14 33355 5688 110550242
Hepatocellular injury 16.78 13.01 43 33326 50599 110505331
Myelosuppression 16.63 13.01 4 33365 94336 110461594
Depressed mood 16.52 13.01 48 33321 60761 110495169
Night sweats 16.47 13.01 10 33359 133973 110421957
Alcohol use 16.45 13.01 12 33357 4110 110551820
Neuropathy peripheral 16.31 13.01 18 33351 179259 110376671
Liposuction 16.30 13.01 3 33366 13 110555917
Nervousness 16.26 13.01 35 33334 36816 110519114
Sciatica 16.12 13.01 4 33365 92395 110463535
COVID-19 16.02 13.01 31 33338 245029 110310901
Myocardial fibrosis 15.95 13.01 9 33360 1986 110553944
Chest X-ray abnormal 15.88 13.01 16 33353 8471 110547459
Breathing-related sleep disorder 15.76 13.01 5 33364 260 110555670
Xanthogranuloma 15.70 13.01 4 33365 93 110555837
Choking 15.64 13.01 21 33348 15089 110540841
Thunderclap headache 15.40 13.01 6 33363 572 110555358
Hepatic function abnormal 15.32 13.01 4 33365 89291 110466639
Wound infection 15.31 13.01 5 33364 96460 110459470
Poor quality product administered 15.18 13.01 12 33357 4629 110551301
Sinusitis 15.02 13.01 43 33326 296645 110259285
Nightmare 15.01 13.01 35 33334 38828 110517102
Oropharyngeal discomfort 14.96 13.01 17 33352 10310 110545620
Grip strength decreased 14.94 13.01 3 33366 80171 110475759
Respiratory arrest 14.87 13.01 45 33324 58254 110497676
Abortion induced 14.79 13.01 15 33354 8004 110547926
Cataract 14.75 13.01 3 33366 79482 110476448
Left ventricular hypertrophy 14.62 13.01 19 33350 13225 110542705
Psychotic disorder 14.61 13.01 41 33328 50896 110505034
Obesity 14.59 13.01 8 33361 113343 110442587
Cardiac death 14.51 13.01 8 33361 1688 110554242
Agitation 14.45 13.01 70 33299 112981 110442949
Coma 14.37 13.01 72 33297 117797 110438133
Brain oedema 14.26 13.01 30 33339 31068 110524862
Retroperitoneal haematoma 14.20 13.01 13 33356 6118 110549812
White blood cell count decreased 14.16 13.01 30 33339 229360 110326570
Tremor 14.15 13.01 107 33262 202125 110353805
Oophoritis 14.03 13.01 4 33365 144 110555786
Peripheral venous disease 14.00 13.01 4 33365 84113 110471817
Pneumothorax spontaneous 13.99 13.01 8 33361 1809 110554121
Hypercholesterolaemia 13.91 13.01 5 33364 90832 110465098
Plethysmography 13.87 13.01 3 33366 33 110555897
Megacolon 13.80 13.01 11 33358 4294 110551636
Hypoxia 13.65 13.01 76 33293 129439 110426491
Non-small cell lung cancer stage IIIB 13.64 13.01 3 33366 36 110555894
Pulmonary fibrosis 13.43 13.01 7 33362 102035 110453895
Malnutrition 13.31 13.01 27 33342 27252 110528678
Upper respiratory tract infection 13.30 13.01 12 33357 131316 110424614
Seizure 13.28 13.01 113 33256 221072 110334858
Premature labour 13.12 13.01 15 33354 9157 110546773
Injection site erythema 13.09 13.01 6 33363 94170 110461760
Restlessness 13.03 13.01 42 33327 56217 110499713
Alcoholism 13.03 13.01 10 33359 3697 110552233
Antipsychotic drug level decreased 13.02 13.01 7 33362 1405 110554525

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07BA01 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
DRUGS USED IN ADDICTIVE DISORDERS
Drugs used in nicotine dependence
FDA CS M0014836 Nicotine
MeSH PA D000077444 Smoking Cessation Agents
MeSH PA D005731 Ganglionic Stimulants
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018679 Cholinergic Agonists
MeSH PA D018722 Nicotinic Agonists
FDA EPC N0000175706 Cholinergic Nicotinic Agonist
CHEBI has role CHEBI:22917 phytogenic insecticide
CHEBI has role CHEBI:35471 psychotropic drug
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:47958 nicotinic acetylcholine receptor agonist
CHEBI has role CHEBI:49110 peripheral nervous system drug
CHEBI has role CHEBI:50846 immunomodulator
CHEBI has role CHEBI:50905 teratogenic agent
CHEBI has role CHEBI:50910 neurotoxin
CHEBI has role CHEBI:52290 mitogen
CHEBI has role CHEBI:59163 biomarker
CHEBI has role CHEBI:76924 plant metabolite
CHEBI has role CHEBI:35469 antidepressant

Related Drugs by ATC class:

N07BA Drugs used in nicotine dependence 1 drug
varenicline

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Nicotine dependence indication 56294008 DOID:0050742
Smoking cessation assistance indication 384742004
Pellagra indication 418186002 DOID:8457
Niacin deficiency indication 418279001
Nicotine Withdrawal Symptoms indication
Hyperlipidemia off-label use 55822004 DOID:1168
Hypophosphatemia contraindication 4996001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Esophagitis contraindication 16761005 DOID:11963
Myocardial infarction contraindication 22298006 DOID:5844
Hyperthyroidism contraindication 34486009 DOID:7998
Temporomandibular joint disorder contraindication 41888000
Low blood pressure contraindication 45007003
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Thromboangiitis obliterans contraindication 52403007 DOID:12918
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Prinzmetal angina contraindication 87343002
Gout contraindication 90560007 DOID:13189
Magnetic resonance imaging contraindication 113091000
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Arterial hemorrhage contraindication 234003006
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Pheochromocytoma contraindication 302835009
Acute coronary syndrome contraindication 394659003
Pharyngitis contraindication 405737000 DOID:2275
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006
Hypertensive urgency contraindication 443482000
Life-Threatening Cardiac Arrhythmias contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.05 Basic
pKa2 3.14 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel AGONIST Ki 8.56 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily D member 3 Ion channel IC50 7.40 WOMBAT-PK
Cytochrome P450 2A6 Enzyme IC50 5.36 WOMBAT-PK
Transient receptor potential cation channel subfamily A member 1 Ion channel ACTIVATOR EC50 4.80 IUPHAR
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel Ki 7.15 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 5.95 WOMBAT-PK
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 7.85 WOMBAT-PK
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 7.64 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel Ki 4.15 CHEMBL
Acetylcholine receptor; alpha1/beta1/delta/gamma Ion channel Ki 5.83 CHEMBL
Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 Ion channel IC50 7.07 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 4.68 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel IC50 7.35 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 5.39 WOMBAT-PK
Acetylcholine-binding protein Secreted Ki 7.20 CHEMBL
Acetylcholine receptor subunit delta Ion channel Ki 9 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel Ki 9.03 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 6.89 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 6.61 CHEMBL
Neuronal acetylcholine receptor subunit alpha-9 Ion channel Kd 8.30 CHEMBL
Neuronal acetylcholine receptor subunit beta-4 Ion channel Ki 7.14 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel Ki 7.33 CHEMBL
Neuronal acetylcholine receptor subunit alpha-2 Ion channel Ki 7.92 CHEMBL
Soluble acetylcholine receptor Secreted Ki 7.52 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 4.64 CHEMBL
Lycopene cyclase Enzyme IC50 5.32 CHEMBL
Nicotinic acetylcholine receptor alpha 5 subunit Ion channel Ki 5.61 CHEMBL
Acetylcholine receptor subunit beta-like 2 Ion channel Ki 5.57 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel Ki 8.72 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel IC50 8.15 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 9 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 6.70 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel Kd 9.40 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor Ion channel Kd 11 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel Ki 7.15 CHEMBL
Acetylcholine receptor Ion channel Ki 5.20 CHEMBL
Muscarinic acetylcholine receptor GPCR IC50 4.55 CHEMBL
Transient receptor potential cation channel subfamily A member 1 Ion channel EC50 5 CHEMBL
Potassium voltage-gated channel subfamily D member 3 Ion channel BLOCKER IC50 7.40 IUPHAR

External reference:

IDSource
4020286 VUID
N0000148163 NUI
D03365 KEGG_DRUG
65-31-6 SECONDARY_CAS_RN
4018610 VANDF
4020286 VANDF
C0028040 UMLSCUI
CHEBI:17688 CHEBI
CHEMBL3 ChEMBL_ID
DB00184 DRUGBANK_ID
CHEMBL3989563 ChEMBL_ID
D009538 MESH_DESCRIPTOR_UI
89594 PUBCHEM_CID
2585 IUPHAR_LIGAND_ID
6M3C89ZY6R UNII
1306106 RXNORM
11529 MMSL
5173 MMSL
5174 MMSL
72003 MMSL
d00316 MMSL
001770 NDDF
003575 NDDF
323283001 SNOMEDCT_US
68540007 SNOMEDCT_US
77544001 SNOMEDCT_US
NCT PDB_CHEM_ID
CHEMBL1201536 ChEMBL_ID
D061485 MESH_DESCRIPTOR_UI
6M3C89ZY6R INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5401 SPRAY, METERED 10 mg NASAL NDA 28 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0029 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0029 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0053 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0170 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0344 LOZENGE 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0456 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0532 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0734 LOZENGE 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0854 GUM, CHEWING 4 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-0873 LOZENGE 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0957 LOZENGE 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-1125 LOZENGE 2 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-1190 LOZENGE 4 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-1352 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-2502 LOZENGE 2 mg ORAL ANDA 14 sections
GOOD SENSE NICOTINE HUMAN OTC DRUG LABEL 1 0113-4111 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-5023 LOZENGE 4 mg ORAL ANDA 15 sections
GOOD SENSE NICOTINE HUMAN OTC DRUG LABEL 1 0113-6020 GUM, CHEWING 2 mg ORAL ANDA 15 sections
GOOD SENSE NICOTINE HUMAN OTC DRUG LABEL 1 0113-7020 LOZENGE 2 mg ORAL ANDA 15 sections
GOOD SENSE NICOTINE HUMAN OTC DRUG LABEL 1 0113-7031 LOZENGE 4 mg ORAL ANDA 15 sections
GOOD SENSE NICOTINE HUMAN OTC DRUG LABEL 1 0113-7969 LOZENGE 2 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-7999 LOZENGE 4 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-8100 GUM, CHEWING 2 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-8600 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Nicorette Original HUMAN OTC DRUG LABEL 1 0135-0157 GUM, CHEWING 2 mg ORAL NDA 13 sections
Nicorette Original HUMAN OTC DRUG LABEL 1 0135-0158 GUM, CHEWING 4 mg ORAL NDA 13 sections
NICODERM CQ HUMAN OTC DRUG LABEL 1 0135-0194 PATCH, EXTENDED RELEASE 21 mg TRANSDERMAL NDA 16 sections
NICODERM CQ HUMAN OTC DRUG LABEL 1 0135-0195 PATCH, EXTENDED RELEASE 14 mg TRANSDERMAL NDA 16 sections
NICODERM CQ HUMAN OTC DRUG LABEL 1 0135-0196 PATCH, EXTENDED RELEASE 7 mg TRANSDERMAL NDA 16 sections